Doxorubicin alters G-protein coupled receptor-mediated vasocontraction in rat coronary arteries
Naunyn-Schmiedeberg's Archives of Pharmacology · 2024
DOI: 10.1007/s00210-024-02988-x ↗Kurz gefasst
Fachartikel in der Zeitschrift Naunyn-Schmiedeberg's Archives of Pharmacology, 2024. Verfasst von Caroline Lozahic und 3 weiteren Autor:innen. Beteiligte Einrichtung: Research Centre for Health & Life Sciences, Coventry University, Alison Gingell Building, Priory Street, Coventry, CV1 5FB, UK. Hauptthemen laut MEDLINE: Doxorubicin, Coronary Vessels, Vasoconstriction. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 54 Literaturangaben. Gefördert von: Coventry University.
Abstract (Originalsprache)
Doxorubicin (Doxo)-associated cardio-and vasotoxicity has been recognised as a serious complication of cancer chemotherapy. The purpose of this novel paper was to determine the effect of Doxo on G-protein coupled receptor (GPCR)-mediated vasocontraction located on vascular smooth muscle cells. Rat left anterior descending artery segments were incubated for 24 h with 0.5 µM Doxo. The vasocontractile responses by activation of endothelin receptor type A (ETA) and type B (ETB), serotonin receptor 1B (5-HT1B) and thromboxane A2 prostanoid receptor (TP) were investigated by a sensitive myography using specific agonists, while the specificity of the GPCR agonists was verified by applying selective antagonists (i.e. ETA and ETB agonist = 10- 14-10- 7.5 M endothelin-1 (ET-1); ETA antagonist = 10 µM BQ123; ETB agonists = 10- 14-10- 7.5 M sarafotoxin 6c (S6c) and ET-1; ETB antagonist = 0.1 µM BQ788; 5-HT1B agonist = 10- 12-10- 5.5 M 5-carboxamidotryptamine (5-CT); 5-HT1B antagonist = 1 µM GR55562; TP agonist = 10- 12-10- 6.5 M U46619; TP antagonist = 1 µM Seratrodast). Our results show that 0.5 µM Doxo incubation of LAD segments leads to an increased VSMC vasocontraction through the ETB, 5-HT1B and TP GPCRs, with a 2.2-fold increase in ETB-mediated vasocontraction at 10- 10.5 M S6c, a 2.0-fold increase in 5-HT1B-mediated vasocontraction at 10- 5.5 M 5-CT, and a 1.3-fold increase in TP-mediated vasocontraction at 10- 6.5 M U46619. Further studies unravelling the involvement of intracellular GPCR signalling pathways will broaden our understanding of the Doxo-induced vasotoxicity, and thus pave the way to mitigate the adverse effects by potential implementation of adjunct therapy options.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Research Centre for Health & Life Sciences, Coventry University, Alison Gingell Building, Priory Street, Coventry, CV1 5FB, UK.
- Research Centre for Health & Life Sciences, Coventry University, Alison Gingell Building, Priory Street, Coventry, CV1 5FB, UK. ab1682@coventry.ac.uk.
Förderung
- Coventry University
Zitieren
APA
Lozahic, C., Maddock, H., Wheatley, M., & Sandhu, H. (2024). Doxorubicin alters G-protein coupled receptor-mediated vasocontraction in rat coronary arteries. Naunyn-Schmiedeberg's Archives of Pharmacology. https://doi.org/10.1007/s00210-024-02988-x
Vancouver
Lozahic C, Maddock H, Wheatley M, Sandhu H. Doxorubicin alters G-protein coupled receptor-mediated vasocontraction in rat coronary arteries. Naunyn-Schmiedeberg's Archives of Pharmacology. 2024. doi:10.1007/s00210-024-02988-x
BibTeX
@article{Lozahic2024,
author = {Lozahic, Caroline and Maddock, Helen and Wheatley, Mark and Sandhu, Hardip},
title = {Doxorubicin alters G-protein coupled receptor-mediated vasocontraction in rat coronary arteries},
journal = {Naunyn-Schmiedeberg's Archives of Pharmacology},
year = {2024},
doi = {10.1007/s00210-024-02988-x}
}
EUVIMED